中华核医学杂志
中華覈醫學雜誌
중화핵의학잡지
CHINESE JOURNAL OF NUCLEAR MEDICINE
2010年
1期
1-4
,共4页
陈永辉%李方%贾兵%景红丽%陈黎波%陈方%王凡%杜延荣%马艳茹%欧阳萌%林岩松%康增寿
陳永輝%李方%賈兵%景紅麗%陳黎波%陳方%王凡%杜延榮%馬豔茹%歐暘萌%林巖鬆%康增壽
진영휘%리방%가병%경홍려%진려파%진방%왕범%두연영%마염여%구양맹%림암송%강증수
神经内分泌瘤%钇放射性同位素%放射疗法%DOTATATE
神經內分泌瘤%釔放射性同位素%放射療法%DOTATATE
신경내분비류%을방사성동위소%방사요법%DOTATATE
Neuroendocrine tumors%Yttrium radioisotopes%Radiotherapy%DOTATATE
目的 评价~(90)Y-生长抑素类似物1,4,7,10-四氮杂十二环-1,4,7,10-四乙酸-octreotate([~(90)Y-(DOTA)~0,Tyr~3]octreotate,即~(90)Y-DOTATATE)联合使用肾保护剂赖氨酸治疗进展期神经内分泌肿瘤的疗效以及不良反应.方法 25例进展期神经内分泌肿瘤患者,经生长抑素受体(SSTR)显像(SRS)诊断为SSTR阳性肿瘤.~(90)Y-DOTATATE在30 min内静脉滴注完毕,用药前后输注赖氨酸.每人完成1～5次治疗,间隔时间为6～9周.每次单程治疗后根据美国国立癌症研究院分级标准(NCIGC)评价不良反应.完成末次治疗后8周依据WHO标准评价疗效.结果 部分缓解1例,占4%(1/25);轻微缓解3例,占12%(3/25);病情稳定16例,占64%(16/25);病情进展5例,占20%(5/25).2例出现不同程度的肾功能损害,3例出现白细胞下降,出现恶心及呕吐症状各3例.结论 以赖氨酸作为肾保护剂,~(90)Y-DOTATATE治疗转移和不能手术的神经内分泌肿瘤是一种有效的新疗法;但应该进一步采取措施减轻肾毒性.
目的 評價~(90)Y-生長抑素類似物1,4,7,10-四氮雜十二環-1,4,7,10-四乙痠-octreotate([~(90)Y-(DOTA)~0,Tyr~3]octreotate,即~(90)Y-DOTATATE)聯閤使用腎保護劑賴氨痠治療進展期神經內分泌腫瘤的療效以及不良反應.方法 25例進展期神經內分泌腫瘤患者,經生長抑素受體(SSTR)顯像(SRS)診斷為SSTR暘性腫瘤.~(90)Y-DOTATATE在30 min內靜脈滴註完畢,用藥前後輸註賴氨痠.每人完成1～5次治療,間隔時間為6～9週.每次單程治療後根據美國國立癌癥研究院分級標準(NCIGC)評價不良反應.完成末次治療後8週依據WHO標準評價療效.結果 部分緩解1例,佔4%(1/25);輕微緩解3例,佔12%(3/25);病情穩定16例,佔64%(16/25);病情進展5例,佔20%(5/25).2例齣現不同程度的腎功能損害,3例齣現白細胞下降,齣現噁心及嘔吐癥狀各3例.結論 以賴氨痠作為腎保護劑,~(90)Y-DOTATATE治療轉移和不能手術的神經內分泌腫瘤是一種有效的新療法;但應該進一步採取措施減輕腎毒性.
목적 평개~(90)Y-생장억소유사물1,4,7,10-사담잡십이배-1,4,7,10-사을산-octreotate([~(90)Y-(DOTA)~0,Tyr~3]octreotate,즉~(90)Y-DOTATATE)연합사용신보호제뢰안산치료진전기신경내분비종류적료효이급불량반응.방법 25례진전기신경내분비종류환자,경생장억소수체(SSTR)현상(SRS)진단위SSTR양성종류.~(90)Y-DOTATATE재30 min내정맥적주완필,용약전후수주뢰안산.매인완성1～5차치료,간격시간위6～9주.매차단정치료후근거미국국립암증연구원분급표준(NCIGC)평개불량반응.완성말차치료후8주의거WHO표준평개료효.결과 부분완해1례,점4%(1/25);경미완해3례,점12%(3/25);병정은정16례,점64%(16/25);병정진전5례,점20%(5/25).2례출현불동정도적신공능손해,3례출현백세포하강,출현악심급구토증상각3례.결론 이뢰안산작위신보호제,~(90)Y-DOTATATE치료전이화불능수술적신경내분비종류시일충유효적신요법;단응해진일보채취조시감경신독성.
Objective To evaluate the effcacy and side effects of [~(90)Y-1,4,7,10-tetraazacyclododecane-N,N',N",N'"-tetraacetic acid (DOTA)~0,Tyr3]octreotate (~(90)Y-DOTATATE) combined with lysine as a renal protective agent.Methods Twenty-five patients with advanced neuroendocrine tumors were confirmed as somatostatin receptor subtype-2 (SSTR2)-positive by somatostatin receptor scintigraphy (SRS).Each patient received 1-5 cycles of treatment and the interval between two cycles of treatment was 6-9 weeks.~(90)Y-DOTATATE was administered intravenously within 30 min.Lysine was injected before and after the administration of ~(90)Y-DOTATATE.After each treatment cycle.the side effects were assessed according to National Cancer Institute Grading Criteria(NCIGC).The etticacy was evaluated by the WHO criteria 8 weeks after the last treatment.Results Pattial remission was found in 1 patient (4%).minor response in 3 patients(12%),stable disease in 16 patients (64%)and tumor progression in 5 patients (20%).Two patients suffered from renal functional injuries and 3 patients developed leukocytopenia.Three patients showed nausea while another 3 patients presented vomiting.Conclusions ~(90)Y-DOTATATE in association with lysine may be a promising treatment method for the patients with metastatic and inoperable neuroendocrine tumors.More research work may be directed to reduce renal injury.
